These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9410542)

  • 21. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
    AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic hepatitis B: back to the future with HBsAg.
    Moucari R; Lada O; Marcellin P
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J; Bani-Sadr F; Gassin M; Raffi F
    Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
    Drake A; Mijch A; Sasadeusz J
    Clin Infect Dis; 2004 Jul; 39(1):129-32. PubMed ID: 15206064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screen for underlying HIV before antiviral treatment for HBV.
    Wong KH; Lee SS; Chan KC
    J Infect; 2005 Aug; 51(2):172-3. PubMed ID: 15936824
    [No Abstract]   [Full Text] [Related]  

  • 28. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN; Liaw YF
    Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
    Yokosuka O
    J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
    [No Abstract]   [Full Text] [Related]  

  • 32. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing clinical development programs for anti-hepatitis B virus drugs.
    Brown NA
    Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
    [No Abstract]   [Full Text] [Related]  

  • 34. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
    Dore GJ; Cooper DA; Barrett C; Goh LE; Thakrar B; Atkins M
    J Infect Dis; 1999 Sep; 180(3):607-13. PubMed ID: 10438346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
    AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lamivudine treatment consensus from relative experts].
    Lamivudine Clinical Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
    [No Abstract]   [Full Text] [Related]  

  • 38. [Entecavir--close perspective for using it].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2006; 60(1):115-8. PubMed ID: 16758749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Factors predicting the disappearance of virus B replication markers following treatment with lamivudine].
    Buffet C
    Presse Med; 2003 Jan; 32(2):53-4. PubMed ID: 12653025
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal?
    Wolters LM; Niesters HG; de Man RA; Schalm SW
    Antiviral Res; 1999 May; 42(1):71-6. PubMed ID: 10333144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.